Add Formweb to your mobile device
Search results for:
trastuzumab
trastuzumab
| Drug Name | Form | Strength | Notes |
|---|---|---|---|
| Herceptin | POWDER FOR INJECTION, INTRAVENOUS | 440 mg | |
| Hercessi | POWDER FOR INJECTION, INTRAVENOUS | strf 150 mg | |
| Hercessi | POWDER FOR INJECTION, INTRAVENOUS | strf 420 mg | |
| Herzuma | POWDER FOR INJECTION, INTRAVENOUS | pkrb 420 mg | |
| Herzuma | POWDER FOR INJECTION, INTRAVENOUS | pkrb 150 mg | |
| Kanjinti | POWDER FOR INJECTION, INTRAVENOUS | anns 420 mg | |
| Kanjinti | POWDER FOR INJECTION, INTRAVENOUS | anns 150 mg | |
| Ogivri | POWDER FOR INJECTION, INTRAVENOUS | dkst 420 mg | |
| Ogivri | POWDER FOR INJECTION, INTRAVENOUS | dkst 150 mg | |
| Ontruzant | POWDER FOR INJECTION, INTRAVENOUS | dttb 150 mg | |
| Ontruzant | POWDER FOR INJECTION, INTRAVENOUS | dttb 420 mg | |
| Trazimera | POWDER FOR INJECTION, INTRAVENOUS | qyyp 420 mg | |
| Trazimera | POWDER FOR INJECTION, INTRAVENOUS | qyyp 150 mg | |
| Herceptin | POWDER FOR INJECTION, INTRAVENOUS | 150 mg |
VIEW MORE Antineoplastic Agents
Last updated: Jan. 9, 2024
- RCRA: Disposal
- RCRA: Management of Pharmaceutical Waste Policy
- Black Box Warning: Cardiomyopathy; infusion reactions, pulmonary toxicity; teratogenicity
- Restricted Restricted Medication
This medication is Inpatient Non-formulary and Restricted to Outpatient Use. Inpatient use requires approval by a physician department leader (i.e. Medical Director or Chair, or hospital CMO) collaborating with a pharmacy leader.
See HERE for more information and workflow.
See HERE for additional pharmacy workflow details.
May be given via hypodermoclysis (HDC/subcutaneous infusion). See Procedure 904.4991